International Partnership for Microbicides Inc

What it reported doing in 2022

Ipm's clinical affairs department remained responsible for quality control and compliance, medical safety, pharmacovigilance, medical affairs, clinical operations, biometrics, public affairs, community public affairs and socio-behavioral sciences for the clinical trials conducted on ipm's products. Key activities in 2022 included: support of the monthly dapivirine vaginal ring (dvr) clinical trials. Ipm worked with clinical trial partner, the united states (us) national institutes of health (nih)-funded microbicide trials network (mtn) on the following clinical trials of the dvr: o mtn-034 (reach): a phase 2a crossover trial evaluating the safety of and adherence to a vaginal matrix ring containing dapivirine and oral emtricitabine/tenofovir disoproxil fumarate in an adolescent and young adult female populationo mtn-042 (deliver): phase 3b, randomized, open label safety trial of dapivirine vaginal ring (vr) and oral truvada use in pregnancyo mtn-043 (b-protected): phase 3b, open-label, safety and drug detection study of dapivirine vaginal ring and oral truvada in breastfeeding mother-infant pairsfurther to this, the clinical affairs team supported the regulatory affairs team in development and completion of the clinical modules and post-approval amendments of the dvr dossiers submitted to regulatory authorities. Prepared for and initiated the clinical bridging trial of ipm's three-month dvr. Building on the promise of ipm's monthly dapivirine ring, ipm developed the three-month dvr, which is designed to increase convenience and reduce annual costs as compared to the monthly dvr. The clinical affairs team worked across departments and with external partners to develop the protocol for the bridging trial and complete all necessary trial preparations. The bridging trial (ipm 054) initiated in q3 2022.supported preparations and initiation of a phase i clinical trials of the dapivirine-contraceptive vaginal ring, a multipurpose prevention technology (mpt). The three-month dapivirine-contraceptive ring is designed to provide slow and simultaneous release of both the antiretroviral (arv) drug dapivirine to prevent HIV and the contraceptive hormone levonorgestrel to prevent unintended pregnancy. A second phase i clinical trial of the reformulated mpt ring (ipm 056/cctn019b) was in planning stages throughout 2022 and initiated in q3 2022. This trial will be conducted by the eunice kennedy shriver national institute of child health and human development (nichd). As of september 30th, 2022, the clinical affairs activities transferred to the population council as part of ipm's dissolution and the associated funding agreement with the population council.

Financial Efficiency

• Mission deployment rate: 79.6%; rating input score 80
• Program expense ratio: 61.9%; rating input score 62
• Fundraising efficiency: $212.01 raised per $1 spent on fundraising; rating input score 92; 92nd percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
• Pay-setting controls: 2 of 6 controls in place; rating input score 33
  • Compensation committee: Pass
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Missing
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: Limited
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 7 of 9 controls in place; rating input score 78
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: -28.5%; rating input score 5; 5th percentile among comparable filings
• Total-asset coverage ratio: 0; rating input score 0; 0th percentile among comparable filings
• Liabilities to assets ratio: Limited
• Officer compensation ratio: 29.8%; rating input score 5; 5th percentile among comparable filings

Growth

• Program expense growth: -9% per year; rating input score 0; 4th percentile among comparable filings
• Revenue growth: -7.9% per year; rating input score 0; 3rd percentile among comparable filings
• Asset growth: -14.2% per year; rating input score 0; 1st percentile among comparable filings